evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

251 questions · 255 findings · 24 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 61 · 23.9%GRADE not reported 40 · 15.7%Very low 45 · 17.6%Low 56 · 22%Moderate 38 · 14.9%High 15 · 5.9%

Summary of findings: Defibrotide vs no treatment

Frequency of adverse events ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease

It is very uncertain whether summary of findings: Defibrotide changes frequency of adverse events ( compared with no treatment (very low certainty).

1 finding from 1 review

Glutamine vs placebo

Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with haematological malignancies

It is very uncertain whether summary of findings: Glutamine changes incidence of hepatic veno‐occlusive disease ( compared with placebo (very low certainty).

1 finding from 1 review

Glutamine vs placebo

All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with haematological malignancies

It is very uncertain whether summary of findings: Glutamine changes all‐cause mortality at 100 days post‐transplant ( compared with placebo (very low certainty).

1 finding from 1 review

Glutamine vs placebo

Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with haematological malignancies

It is very uncertain whether summary of findings: Glutamine changes mortality attributable to hepatic veno‐occlusive disease ( compared with placebo (very low certainty).

1 finding from 1 review

Ursodeoxycholic acid vs placebo or no treatment

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

Summary of findings: Ursodeoxycholic acid may leads to lower all‐cause mortality at 100 days post‐transplant ( compared with placebo or no treatment (low certainty).

1 finding from 1 review

Fresh frozen plasma vs no treatment

Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Fresh frozen plasma changes incidence of hepatic veno‐occlusive disease ( compared with no treatment (very low certainty).

1 finding from 1 review

Summary of findings: Antithrombin III plus heparin vs heparin

Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Antithrombin III plus heparin changes incidence of hepatic veno‐occlusive disease ( compared with heparin alone (very low certainty).

1 finding from 1 review

Ursodeoxycholic acid vs placebo or no treatment

Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Ursodeoxycholic acid changes mortality attributable to hepatic veno‐occlusive disease ( compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Summary of findings: Antithrombin III plus heparin vs heparin

Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Antithrombin III plus heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with heparin alone (very low certainty).

1 finding from 1 review